Hematopoietic Stem Cell TransplantationTransplantation, HomologousPeripheral Blood Stem Cell TransplantationTransplantation, AutologousGraft vs Host DiseaseTransplantation ConditioningBone Marrow TransplantationHematologic NeoplasmsMyeloablative AgonistsHematopoietic Stem Cell MobilizationTissue DonorsTreatment OutcomeWhole-Body IrradiationStem Cell TransplantationUnrelated DonorsGraft SurvivalImmunosuppressive AgentsHistocompatibility TestingGraft vs Tumor EffectBusulfanCord Blood Stem Cell TransplantationVidarabineTransplantation ChimeraGranulocyte Colony-Stimulating FactorLeukapheresisHematopoietic Stem CellsRecurrenceGraft vs Leukemia EffectHistocompatibilityRetrospective StudiesLeukemia, Myeloid, AcuteLeukemiaStem CellsCombined Modality TherapyAntigens, CD34Remission InductionSurvival AnalysisBlood Component RemovalSiblingsCyclophosphamideChimerismSurvival RateDisease-Free SurvivalDonor SelectionMyelodysplastic SyndromesHLA AntigensHematologic DiseasesMelphalanLymphoma, Non-HodgkinMultiple MyelomaTime FactorsAcute DiseaseCyclosporinePrecursor Cell Lymphoblastic Leukemia-LymphomaAntineoplastic Combined Chemotherapy ProtocolsMinor Histocompatibility AntigensLeukemia, Myelogenous, Chronic, BCR-ABL PositiveFollow-Up StudiesT-LymphocytesSalvage TherapyCytomegalovirus InfectionsGraft RejectionAllograftsImmunosuppressionTransplantationLymphocyte DepletionHematopoiesisLymphomaBlood CellsLiving DonorsKidney TransplantationRisk FactorsBlood DonorsAnemia, AplasticLiver TransplantationChronic DiseaseBlood Cell CountTransplantation ImmunologyEtoposideLymphoproliferative DisordersAntineoplastic AgentsMycophenolic AcidInfectionPrognosisAntineoplastic Agents, AlkylatingTransplantation, IsogeneicProspective StudiesTacrolimusHodgkin DiseaseThiotepaBone Marrow CellsFlow CytometryOpportunistic InfectionsIncidenceBone Marrow PurgingCell TransplantationImmunocompromised HostAge FactorsMycosesNeoplasms